- Home
- QTTB vs EH Comparison
QTTB vs EH Comparison
Compare QTTB & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | EH |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 314.0M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | QTTB | EH |
|---|---|---|
| Price | $8.75 | $3.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $39.67 | $7.83 |
| AVG Volume (30 Days) | 384.0K | ★ 685.2K |
| Earning Date | 11-04-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | $1.85 |
| Revenue Next Year | N/A | $70.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $3.31 |
| 52 Week High | $23.57 | $15.32 |
Technical Indicators
Market Signals| Indicator | QTTB | EH |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 43.69 |
| Support Level | $8.23 | $3.31 |
| Resistance Level | $9.25 | $4.27 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 34.98 | 20.14 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).